Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3328117 | Acta Haematologica Polonica | 2015 | 5 Pages |
Abstract
Polycythaemia Vera (PV) and Essential Thrombocythaemia (ET) are classical Chronic Myeloproliferative Neoplasms BCR-ABL(-). Despite their low incidence rates, survival of PV and ET patients is high, thereby making up a significant proportion of those cared for at the haematology clinic. Most patients requiring cytoreductive therapy receive hydroxycarbamide (HU) as the drug of choice, however around 20% prove to be either HU resistant or intolerant. In such cases, this article discusses the therapeutic options available for their treatment.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Joanna Góra-Tybor,